MRSA Drug Futures23 Nov 2010 • by Natalie Aster
LONDON – “Three new products expected to launch from 2011 will add US$1.1 billion to the sector’s value taking the total MRSA market to in excess of US$4.1 billion. Pfizer will continue to dominate but its percentage share will diminish: declining revenues from Zyvox will be offset by increasing sales of Tygacil which will result in a small decline in overall revenues.”
At the same time Cubist Pharmaceuticals’ Cubicin and LEO Pharma’s Fucidin are expected to show strong growth, the former becoming the most valuable product for treating MRSA with almost blockbuster sales of US$911 million in 2016.
Of the new products expected to launch, Paratek Pharmaceuticals/Novartis’ PTK 0796 has an 80% chance of reaching the market, largely due to the drug’s advantageous mode of action and proof of concept and is forecast to achieve sales of US$454 million by 2016.
Published: September 2010
Price: US$ 1,740.00 US$ 1,395.00
Offer valid until December 31, 2010!
Report Sample Abstract
A number of drugs with different mechanisms of action have been approved for the treatment of infections caused by MRSA and there is a mixture of antibiotic classes in development for MRSA, including older ones, such as glycopeptides, modified versions of older classes, such as neoglycosides, and combinations, such as heterodimers (betalactam+glycopeptide).
The problem of ever-evolving resistance remains, and it is only a matter of time before the resourceful bacteria evolve once again to become resistant to novel antibiotic classes. It is in this regard that perhaps immunotherapies and vaccines may be the real key to success against MRSA.
Espicom has identified 10 agents in Phase II & III trials for the treatment of MS that have potential to make a significant impact on the market. For each product the report provides a standardised review of the factors which can affect clinical and commercial performance. The first five criteria are used to determine the competitor ratio analysis score (CRA), each attracting a maximum of ten points, resulting in a maximum score of 50 overall:
- Mode of action;
- Proof of concept;
- Risks associated with drug development;
- Company expertise;
- Competition within the market-place;
- Sales forecast (for key late-stage and launched products);
- CRA score;
- Clinical trial results.
To order the report or ask for free sample pages contact firstname.lastname@example.org